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Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia
regarding clonal evolution to myelodysplastic syndrome (MDS) in a subset of susceptible patients. 4 However, in contrast to other thrombopoietin receptor (TPO-R, MPL) agonists, EPAG has also been shown in-vitro to directly inhibit cell growth of leukemic cells while the underlying mechanisms are still under investigation. 5, 6 A formal proof of that observation in patients is still missing.
We report a 70 years old male patient with a nucleophosmin 1 mutated (NPM1 mut ) acute myelogenous leukemia (AML) and a normal karyotype (NK) relapsing one year after completion of several courses of conventional chemotherapy including high-dose cytarabine based consolidation. The patient failed subsequent treatment with azacitidine and entered a clinical trial (NCT00903422) investigating single agent EPAG in patients with refractory AML and thrombocytopenia. 7 He received EPAG continuously starting with 100mg/day, which was subsequently increased up to a dose of 300mg daily. As shown in Figure 1A the patient achieved a bone marrow response with less than 5% blasts but in the absence of recovery of peripheral counts (CRi). He remained in CRi for another 3 months without improvements in peripheral blood counts ( Figure 1D ) and ultimately progressed 5 months after initiation of single agent EPAG. Potential anti-proliferative effects of EPAG on leukemic cells in-vitro have been shown to occur independently of MPL expression. 6 In line with these data we observed a significantly lower MPL expression in our index patient as well as in a cohort of NK NPM1 mut AML patients compared to wildtype cases ( Figure 1B ). Since MPL is predominantly expressed on CD34+ progenitor cells these data are also in agreement with the notion that NPM1 mut AML often lack CD34 expression compared to wild type cases.
In order to get more insights into the mechanisms of response and subsequent clonal evolution during single agent EPAG therapy, we conducted comprehensive molecular analyses of DNA derived from sequential bone marrow biopsies of this patient. Samples (prior to EPAG, at remission and relapse) were subjected to genome-wide copy number analysis using Affymetrix SNP 6.0 arrays but no acquired copy number alterations could be At the time of progression, NGS detected the emergence of an NRAS c.37G>C mutation not detected at earlier time points in addition to a sharp increase in NPM1 mut levels ( Figure 1C ), consistent with either the expansion of a pre-existent EPAG resistant NRAS c37G>C mutated subclone or the de-novo acquisition of an NRAS c37G>C mutation. These data further strengthen the potential of EPAG to stimulate early hematopoietic progenitor cells outside the common indication in ITP. In agreement with other reports we do not believe that EPAG promotes leukemic evolution by stimulation of the MPL receptor, but think that our case further illustrates that it may even have a direct MPL-independent (although short-lived)
anti-leukemic effect in-vivo. It the lights of a recently presented clinical trial on EPAG in refractory AML 7 it seems, however, that this effect is applicable only to a subgroup of patients, the characteristics of which remain to be defined. Our case also emphasizes that close monitoring and surveillance of these patients during treatment with a potential "stem cell cookie" 3 are mandatory. 
